Yasuharu Imai

Ikeda, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 101 publications

Magnetic resonance imaging-based risk factors of hepatocellular carcinoma after direct-acting antiviral therapy: A multicenter observational study.

Magnetic resonance imaging-based risk factors of hepatocellular carcinoma after direct-acting antiviral therapy: A multicenter observational study.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: April 05, 2023

The FIB-4 Index Predicts the Development of Liver-Related Events, Extrahepatic Cancers, and Coronary Vascular Disease in Patients with NAFLD.

The FIB-4 Index Predicts the Development of Liver-Related Events, Extrahepatic Cancers, and Coronary Vascular Disease in Patients with NAFLD.

Journal: Nutrients

Published: November 23, 2022

Letter: serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination-authors' reply.

Letter: serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination-authors' reply.

Journal: Alimentary pharmacology & therapeutics

Published: April 01, 2022

Improved Liver Function After Sustained Virologic Response Enhanced Prognosis in Hepatitis C with Compensated Advanced Liver Fibrosis.

Improved Liver Function After Sustained Virologic Response Enhanced Prognosis in Hepatitis C with Compensated Advanced Liver Fibrosis.

Journal: Digestive diseases and sciences

Published: January 13, 2022

Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma.

Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma.

Journal: Hepatology (Baltimore, Md.)

Published: January 13, 2022

Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy.

Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy.

Journal: Cancers

Published: January 09, 2022

Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma.

Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: January 06, 2022

Letter: evaluation and proposed reclassification of HCC prediction model of Tahata et al. in chronic hepatitis C genotype 4 patient. Authors' reply.

Letter: evaluation and proposed reclassification of HCC prediction model of Tahata et al. in chronic hepatitis C genotype 4 patient. Authors' reply.

Journal: Alimentary pharmacology & therapeutics

Published: December 31, 2021

Serum Mac-2 binding protein level predicts the development of liver-related events and colorectal cancer in patients with NAFLD.

Serum Mac-2 binding protein level predicts the development of liver-related events and colorectal cancer in patients with NAFLD.

Journal: Hepatology communications

Published: December 22, 2021

Prediction Model for Intrahepatic Distant Recurrence After Radiofrequency Ablation for Primary Hepatocellular Carcinoma 2 cm or Smaller.

Prediction Model for Intrahepatic Distant Recurrence After Radiofrequency Ablation for Primary Hepatocellular Carcinoma 2 cm or Smaller.

Journal: Digestive diseases and sciences

Published: December 17, 2021

Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy.

Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: September 28, 2021

Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination.

Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination.

Journal: Alimentary pharmacology & therapeutics

Published: August 13, 2021

Showing 1-12 of 101

Last Updated: 09/26/2026